Enhancing Hiv Vaccine Efficacy in High-Risk Drug Users

The summary for the Enhancing Hiv Vaccine Efficacy in High-Risk Drug Users grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Enhancing Hiv Vaccine Efficacy in High-Risk Drug Users: NIDA invites domestic and international research applications related to the determination of HIV vaccine efficacy in high-risk drug-using populations. In drug-using populations, full efficacy of HIV vaccine candidates, currently in development, will be achieved through vaccine trials evaluating the candidate vaccine in combination with intervention(s) for substance abuse and related comorbidities. The current initiative seeks to support clinical research to develop strategies for implementing promising HIV vaccine candidates in cohorts of individuals at high risk for HIV infection and who abuse drugs or who are at high risk to abuse drugs. Most exposure to HIV is through high-risk behaviors and, in a substantial proportion of cases, individuals who are at high risk for HIV infection will likely remain at high risk for decades. A successful preventive or therapeutic vaccine for HIV/AIDS will, therefore, have to induce long-lasting immune responses or be given as boosts on a regular basis. Further, few studies have assessed the impact of behavioral interventions and/or treatment interventions for substance abuse on HIV incidence. Deployment of a vaccine that has shown efficacy in clinical trials - in the absence of the concurrent intervention for high-risk activity - could result in a vaccine whose effectiveness proves lower than its efficacy. Thus, behavioral and/or treatment interventions for substance abuse need to be identified and tested in populations at high-risk for HIV infection and targeted for phase III vaccine trials. The purpose of this RFA is to determine the validity of novel approaches to address the prevention of HIV and related blood-borne and sexually transmitted infections; as well as, to establish and study cohorts of high- risk drug users in the context of the developing HIV vaccine. Well-designed, targeted counseling and other interventions, such as chemotherapy for drug abuse, are needed to be adaptable and responsive to changing patterns of drug use and increasing risk behaviors of individuals exposed to first generation HIV vaccines. It is important to assess the effectiveness, sustainability, and durability of HIV prevention interventions and treatment interventions for substance users/abusers in concert with cohort HIV vaccinations studies. The data generated from such studies would provide efficacious mass vaccination paradigms for high-risk drug users.
Federal Grant Title: Enhancing Hiv Vaccine Efficacy in High-Risk Drug Users
Federal Agency Name: National Institutes of Health
Grant Categories: Health Education
Type of Opportunity: Discretionary
Funding Opportunity Number: RFA-DA-03-002
Type of Funding: Grant
CFDA Numbers: 93.279
CFDA Descriptions: Drug Abuse Research Programs
Current Application Deadline: No deadline provided
Original Application Deadline: Apr 14, 2003
Posted Date: Jan 15, 2003
Creation Date: May 14, 2003
Archive Date: May 14, 2003
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching: No
Applicants Eligible for this Grant
State governments County governments City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification)
Link to Full Grant Announcement
Information not provided
Grant Announcement Contact
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster OERWebmaster@od.nih.gov NIH OER Webmaster
Similar Government Grants
Single Cell Opioid Responses in the Context of HIV (SCORCH) Program: Data Coordination, An...
Targeting Inflammasomes in Substance Abuse and HIV (R01 Clinical Trial Not Allowed)
Research Networks for the Study of Recovery Support Services for Persons Treated with Medi...
The Rat Opioid Genome Project: Clinical Trials not Allowed (U01- Clinical Trial Not Allowe...
The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Required)
NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards
Drug Abuse Aspects of Hiv/Aids and Other Infections
Epidemiology of Drug Abuse
More Grants from the National Institutes of Health
Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...
Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...
Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 ...
Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...
Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Scree...

FederalGrants.com is not endorsed by, or affiliated with, any government agency. Copyright ©2019 FederalGrants.com